

**ASX RELEASE**

**12 July 2024**

**BIOSHARES CONFERENCE PRESENTATION**

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to announce that Amplia’s CEO and MD Dr Chris Burns is presenting today at the annual Bioshares conference, being held in Fremantle, WA, Australia. The presentation outlines recent progress and development plans.

A copy of the presentation is attached to this announcement.

This ASX announcement was approved and authorised for release by the CEO.

- End -

**Investor Contact:**

Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)

**Media Contact:**

HACK Director, Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit [www.ampliatx.com](http://www.ampliatx.com) and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx), [Threads](https://www.threads.net/@ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/amplia-therapeutics).